Estimated reading time: 6 minutes

Nanoparticles, defined as materials in the nanorange (1–100 nm), possess unique optical, magnetic, and electrical properties that make them ideal for drug delivery. They are engineered to navigate biological barriers—systemic, microenvironmental, and cellular—which vary across patient populations and diseases. Research suggests that only 0.7% of administered nanoparticle doses reach solid tumors on average, highlighting the need for improved delivery efficiency . By enhancing drug solubility, targeting specificity, and controlled release, nanoparticles address limitations of traditional chemotherapy, which often lacks specificity and induces multidrug resistance.

Challenges in Drug Delivery and How Nanoparticles Address Them

Traditional drug delivery faces several hurdles, including:

Poor Solubility: Many chemotherapeutic agents, especially hydrophobic ones, have low water solubility, limiting absorption. Nanoparticles like liposomes and polymeric nanoparticles encapsulate these drugs, improving solubility and stability. For instance, liposomes can deliver doxorubicin, enhancing its bioavailability .
Low Bioavailability: Drugs may be rapidly metabolized or cleared, reducing therapeutic effects. Nanoparticles extend drug half-life by protecting them from degradation, as seen with mesoporous silica nanoparticles delivering paclitaxel and gemcitabine .
Targeting Specificity: Achieving precise delivery to tumor sites while sparing healthy tissues is challenging. Nanoparticles leverage the enhanced permeability and retention (EPR) effect for passive targeting and can be functionalized with ligands for active targeting, such as gold nanoparticles conjugated with antibodies for prostate cancer .
Toxicity: High doses can cause systemic toxicity. By targeting drugs directly to tumors, nanoparticles reduce exposure to healthy cells, minimizing side effects, as demonstrated with albumin-based nanoparticles like Abraxane® for metastatic breast cancer .
Drug Resistance: Cancer cells often develop resistance, reducing treatment efficacy. Nanoparticles overcome this by co-delivering multiple drugs or silencing resistance genes, such as siRNA via polymetformin nanoparticles for melanoma .

Nanoparticles also address biological barriers, such as crossing the blood-brain barrier for brain cancer treatment using spherical nucleic acids (SNAs), with studies showing improved outcomes Brain cancer treatment. Their ability to respond to stimuli like pH, temperature, or light further enhances controlled release, improving therapeutic precision.

Types of Nanoparticles and Their Applications

The following table lists the types of nanoparticles used in cancer treatment, their descriptions, applications, and advantages, as identified in recent research:

Type	Description	Applications	Advantages
Liposomes	Spherical vesicles with lipid bilayer, encapsulate drugs.	Deliver doxorubicin (e.g., Doxil® for breast cancer), reduce toxicity.	Biocompatible, EPR effect, controlled release.
Polymeric Nanoparticles	Made from biodegradable polymers like PLGA, deliver drugs/proteins.	Chemotherapy, gene therapy for breast/lung cancer.	Protect drugs, enhance stability, surface functionalization.
Micelles	Self-assembled, hydrophobic core, hydrophilic shell, for lipophilic drugs.	Deliver paclitaxel for breast/ovarian cancer.	Small size (<50 nm), tumor penetration, stimuli-responsive.
Gold Nanoparticles (AuNPs)	Metallic, optical/photothermal properties.	Photothermal therapy (PTT), imaging, drug delivery (prostate cancer).	Inert, non-toxic, ligand functionalization.
Iron Oxide Nanoparticles	Magnetic, superparamagnetic properties.	MRI, hyperthermia therapy, drug delivery.	High targeting specificity, controlled release.
Mesoporous Silica NPs (MSNPs)	Porous silica, high surface area for drug loading.	Deliver camptothecin for colorectal cancer, chemotherapy.	High drug-loading capacity, biocompatibility.
Quantum Dots (QDs)	Semiconductor, fluorescence properties.	Cancer imaging, limited drug delivery.	Excellent for imaging, production challenges.
Carbon-Based NPs	Includes carbon nanotubes, graphene oxide.	Deliver doxorubicin, thermal ablation therapy.	High drug-loading, multimodal therapy potential.
Nanoemulsions (NEs)	Colloidal oil-water dispersions, 10-1000 nm.	Deliver docetaxel for various cancers.	Optical clarity, stability, biodegradability.
Protein Nanoparticles	Made from albumin, natural transporters.	Deliver paclitaxel (Abraxane® for breast cancer).	Low toxicity, facilitate transcytosis.
Metal-Organic Frameworks	Porous crystalline, metal ions, organic ligands.	Drug delivery, PDT for breast/cervical cancer.	High drug-loading, tunable structures.
Cell Membrane-Coated NPs	Coated with natural cell membranes for biocompatibility.	Immunotherapy, deliver immunostimulatory agents.	Immune evasion, tumor-specific targeting.
Exosomes/Extracellular Vesicles	Naturally occurring, derived from cells.	Deliver nucleic acids/drugs for immunotherapy, gene therapy.	Biocompatible, natural targeting, low immunogenicity.

These nanoparticles are tailored for specific applications, with recent studies showing their efficacy in clinical and preclinical settings .

Integration with Advanced Therapies

Nanoparticles are increasingly integrated with advanced cancer therapies, enhancing their function and addressing limitations. Below, we explore their role in CAR-T cell therapy, immunotherapy, gene therapy, and photodynamic/photothermal therapy (PDT/PTT).

CAR-T Cell Therapy

CAR-T cell therapy involves engineering T cells to express chimeric antigen receptors (CARs) targeting cancer cells, particularly effective for hematological malignancies but challenging for solid tumors. Nanoparticles enhance this therapy by:

In Vivo Engineering: A 2017 study in Nature Nanotechnology demonstrated nanoparticles carrying DNA to engineer T cells in mice, targeting CD19-positive leukemia cells. This method simplifies manufacturing, potentially enabling “off-the-shelf” treatments, with treated mice living 58 days longer than controls . Recent advancements in 2024 from the University of Pennsylvania used lipid nanoparticles to reduce manufacturing time to 24 hours, improving accessibility .
Overcoming Solid Tumor Challenges: Nanoparticles address tumor microenvironment barriers, enhancing T cell activation and delivery, as discussed in a 2021 Frontiers in Immunology review for CNS tumors .

Immunotherapy

Nanoparticles enhance immunotherapy by delivering immunostimulatory and immunomodulatory molecules, reducing side effects. They are used in nanoparticle-based vaccines, co-delivering antigens and adjuvants for T cell activation, and in situ vaccination with artificial antigen-presenting cells (aAPCs). For example, lipid nanoparticles have been explored for mRNA cancer vaccines, similar to COVID-19 vaccines, improving immune responses .

Gene Therapy

In gene therapy, nanoparticles encapsulate nucleic acids (DNA, RNA, siRNAs, mRNAs, miRNAs) for extended half-life and controlled release, targeting undruggable cancer proteins. Studies show SNAs treating brain cancer by crossing the blood-brain barrier, and siRNA via polymetformin nanoparticles suppressing drug resistance in melanoma . This approach enhances treatment outcomes for conditions like brain cancer and drug-resistant cancers.

Photodynamic and Photothermal Therapy

Nanoparticles like gold and silica are used in PDT and PTT. In PDT, they generate reactive oxygen species (ROS) under light exposure, killing cancer cells, while in PTT, they convert light into heat for tumor ablation. Gold nanoparticles are particularly effective in PTT for head and neck squamous cell carcinoma, with studies showing improved tumor penetration .

Combination Therapies

Nanoparticles enable combination therapies, co-delivering chemotherapeutic agents, immunotherapies, and gene therapies. This multifunctionality enhances efficacy and overcomes resistance, with recent research exploring hybrid nanoparticles combining properties for better outcomes .

Latest Research and Developments

Recent studies as of May 24, 2025, highlight significant advancements:

A 2024 study from Penn Engineering showed lipid nanoparticles speeding up CAR-T cell manufacturing, potentially reducing costs and improving access .
A 2023 review in Signal Transduction and Targeted Therapy discussed smart nanoparticles responding to biological cues, improving precision in cancer treatment .
Preclinical results from 2024 indicate lipid nanoparticles enhancing CAR-T therapy safety and efficacy, with ongoing clinical trials expected to validate findings .

Challenges and Future Directions

Despite progress, challenges remain, including toxicity concerns, variable EPR effects across patients, and clinical translation hurdles. Only a few nanoparticle formulations, like Doxil® and Abraxane®, are FDA-approved, with about 75 in clinical trials as of recent reports . Future research aims to develop smart, stimuli-responsive nanoparticles and address long-term safety, potentially expanding their use in combination therapies.

Conclusion

Nanoparticles are revolutionizing cancer treatment by overcoming drug delivery challenges and enhancing advanced therapies like CAR-T cell therapy, immunotherapy, and gene therapy. Their ability to improve targeting, reduce side effects, and integrate with innovative treatments positions them as a cornerstone of precision medicine. As research continues, addressing clinical translation and safety will be key to realizing their full potential.

Citations

Waqas Khan

Waqas Khan is a dedicated writer and blogger who has been crafting compelling content since 2012. Specializing in science and technology topics, he has built a reputation for translating complex technical concepts into reader-friendly articles. His work demonstrates a deep understanding of emerging technologies and scientific advancements, making him a reliable voice in the digital content space.